Non-profitBelgiumfesca-scleroderma.eu
None yet. When a new project in the record names FESCA as owner, partner or investor, it shows here.
First-in-class oral PDE4B inhibitor approved for adults with IPF and PPF after Phase III trials showed slower lung function decline and a favourable tolerability profile.
